Atopic dermatitis market to reach $16.7b by 2030 across seven major markets

Pharmaceutical firms are urged to capitalise on current trends in AD trials.

The atopic dermatitis (AD) market is projected to reach $16.7b by 2030 across the seven major markets (7MM), notably the US, France, Germany, Italy, Spain, the UK, and Japan, according to GlobalData.

The report revealed that as of 2020, approximately 781 million patients within the 7MM were reported to have AD, with this figure expected to grow.

The existing treatment paradigm primarily includes topical corticosteroids, moisturisers, antihistamines, and recently approved inhibitors. However, these therapies often provide temporary relief and may come with potential side effects.

Filippos Maniatis, a healthcare analyst at GlobalData, noted that pharmaceutical companies should capitalise on current trends in AD trials by investing in research and development (R&D), establishing collaborations, and adopting patient-focused strategies.

The analyst further cited existing partnerships in the sector, notably the collaboration between Regeneron and Sanofi, which led to the development of Dupixent, a treatment for moderate to severe AD. 

“The anticipated sales of Dupixent for AD are projected to reach $6.2b in 2030, highlighting the significant rewards and substantial potential in this rapidly evolving market,” Maniatis added.